Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.43 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446655 | 0.92 | HDAC1 (0.50) | PTPN1SLC17A5HDAC1HDAC2 | |
| SCHEMBL17446653 | 0.84 | PTPN1 (0.48) | PTPN1HDAC1HDAC2TNF | |
| SCHEMBL29480470 | 0.84 | CTSK (0.57) | PTPN1 | |
| SCHEMBL29715771 | 0.83 | PTPN1 (0.46) | PTPN1HDAC1HDAC2TNF | |
| SCHEMBL17446656 | 0.83 | PTPN1 (0.46) | PTPN1HDAC1HDAC2TNF | |
| SCHEMBL17446645 | 0.83 | HDAC1 (0.57) | SLC17A5HDAC1HDAC2TNF | |
| SCHEMBL23811018 | 0.82 | KMT2A (0.52) | HDAC1HDAC2TNF | |
| SCHEMBL13716720 | 0.81 | SLC17A5 (0.53) | PTPN1SLC17A5HDAC1HDAC2TNF | |
| SCHEMBL29480487 | 0.80 | CTSK (0.51) | PTPN1HDAC1HDAC2TNF | |
| SCHEMBL17446669 | 0.79 | HDAC1 (0.49) | PTPN1SLC17A5HDAC1HDAC2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | PTPN1 2412/4885SLC17A5 3191/4885HDAC1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.